Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

JCR Pharmaceuticals Co Ltd Raises Mid-year Consolidated Outlook for FY 2014


Wednesday, 25 Sep 2013 02:30am EDT 

JCR Pharmaceuticals Co Ltd announced that it has raised its mid-year consolidated outlook for revenue from JPY 7,200 million to JPY 7,360 million, operating profit from JPY 390 million to JPY 600 million, ordinary profit from JPY 400 million to JPY 620 million, net profit from JPY 250 million to JPY 380 million, and earnings per share from JPY 7.87 to JPY 11.96, for the fiscal year ending March 2014. The Company raised its mid-year consolidated outlook mainly due to the increase in sales of growth hormone agent and decrease in development expense. 

Latest Developments for JCR Pharmaceuticals Co Ltd

Company Quote

2431.0
12.0 +0.50%
11 Jul 2014